Nama's AI scorecard currently rates Ligand Pharmaceuticals Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is LGND's P/E ratio?

Ligand Pharmaceuticals trades at a trailing price-to-earnings ratio of 35.2.

When does LGND report earnings?

Ligand Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $2.87.

What is the LGND price target?

The median analyst price target from 12 analysts is $350.00, with a range of $247.00 – $406.00.

Is LGND Shariah compliant?

Nama's AAOIFI-style screen reads Ligand Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Ligand Pharmaceuticals (LGND)

Healthcare · Biotechnology · NASDAQ

Ligand Pharmaceuticals (LGND) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.12B, a trailing price-to-earnings ratio of 35.2 and a free-cash-flow yield of 0.6%. Over the most recent reported fiscal year, revenue grew 60.4% and free cash flow per share fell 55.7%. Nama's AI scorecard rates it Buy, 6.9 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +40.9% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-6.2%

How far the last close sits under the highest price of the past five years.

Market cap	$6.12B
Trailing P/E	35.2
Price / book	6.3
Price / sales	24.1
FCF yield	0.6%
Dividend yield	—
Gross margin	95.4%
Operating margin	34.5%
Net margin	67.9%
Revenue growth (YoY)	+60.4%
Revenue growth (3-yr annual)	+11.0%
EPS growth (YoY)	+40.8%
FCF/share growth (YoY)	-55.7%
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

LGND earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $2.87). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$2.67	$2.33	+14.6%	$78.75M
Q2 2026	Aug 6, 2026	$2.37	$1.95	+21.5%	$63.69M
Q1 2026	May 7, 2026	$1.63	$1.80	-9.4%	$51.72M
Q4 2025	Feb 26, 2026	$2.02	$1.50	+34.7%	$59.67M

LGND analyst price target

Median target $350.00 from 12 analysts, ranging $247.00 – $406.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live LGND data on Nama Insights →

Recent Congressional trades

Ligand Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 8, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 13, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Feb 13, 2026

LGND FAQ

Is LGND a buy?: Nama's AI scorecard currently rates Ligand Pharmaceuticals Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LGND's P/E ratio?: Ligand Pharmaceuticals trades at a trailing price-to-earnings ratio of 35.2.
When does LGND report earnings?: Ligand Pharmaceuticals's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $2.87.
What is the LGND price target?: The median analyst price target from 12 analysts is $350.00, with a range of $247.00 – $406.00.
Is LGND Shariah compliant?: Nama's AAOIFI-style screen reads Ligand Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.